{"filing":{"accession_number":"0001790340-26-000059","cik":"0001790340","ticker":"IMRX","company_name":"Immuneering Corp","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"imrx-20260601.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm"},"events":[{"id":7987,"run_id":7011,"accession_number":"0001790340-26-000059","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Immuneering announced updated Phase 2a clinical trial data for atebimetinib in pancreatic cancer showing a 17.3-month median overall survival versus 8.5 months for standard of care, along with a 36% overall response rate and 82% disease control rate. While this is a clinical trial update rather than a formal earnings release or other specifically enumerated event type, the positive efficacy and safety data for a lead product candidate in a pivotal development stage would materially affect investor assessment of the company's prospects, particularly given the announced Phase 3 trial initiation expected in mid-2026.","company_name":"Immuneering Corp","ticker":"IMRX","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3386,"accession_number":"0001790340-26-000059","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Immuneering announced updated Phase 2a clinical trial data for atebimetinib in pancreatic cancer showing a 17.3-month median overall survival versus 8.5 months for standard of care, along with a 36% overall response rate and 82% disease control rate. While this is a clinical trial update rather than a formal earnings release or other specifically enumerated event type, the positive efficacy and safety data for a lead product candidate in a pivotal development stage would materially affect investor assessment of the company's prospects, particularly given the announced Phase 3 trial initiation expected in mid-2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:10:35.686595+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3386,"accession_number":"0001790340-26-000059","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Immuneering announced updated Phase 2a clinical trial data for atebimetinib in pancreatic cancer showing a 17.3-month median overall survival versus 8.5 months for standard of care, along with a 36% overall response rate and 82% disease control rate. While this is a clinical trial update rather than a formal earnings release or other specifically enumerated event type, the positive efficacy and safety data for a lead product candidate in a pivotal development stage would materially affect investor assessment of the company's prospects, particularly given the announced Phase 3 trial initiation expected in mid-2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:10:35.686595+00:00","company_name":"Immuneering Corp","ticker":"IMRX","filing_date":"2026-06-01"}]}